{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T07:17:40Z","timestamp":1782544660830,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-002454"],"award-info":[{"award-number":["INV-002454"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1210548"],"award-info":[{"award-number":["OPP1210548"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Peierls Foundation"},{"DOI":"10.13039\/100017433","name":"That Man May See","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017433","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Biannual distribution of azithromycin to children 1\u201359\u2009months old reduced mortality by 14% in a cluster-randomized trial. The World Health Organization has proposed targeting this intervention to the subgroup of children 1\u201311\u2009months old to reduce selection for antimicrobial resistance. Here, we describe a trial designed to determine the impact of age-based targeting of biannual azithromycin on mortality and antimicrobial resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>AVENIR is a cluster-randomized, placebo-controlled, double-masked, response-adaptive large simple trial in Niger. During the 2.5-year study period, 3350 communities are targeted for enrollment. In the first year, communities in the Dosso region will be randomized 1:1:1 to 1) azithromycin 1\u201311: biannual azithromycin to children 1\u201311\u2009months old with placebo to children 12\u201359\u2009months old, 2) azithromycin 1\u201359: biannual azithromycin to children 1\u201359\u2009months old, or 3) placebo: biannual placebo to children 1\u201359\u2009months old. Regions enrolled after the first year will be randomized with an updated allocation based on the probability of mortality in children 1\u201359\u2009months in each arm during the preceding study period. A biannual door-to-door census will be conducted to enumerate the population, distribute azithromycin and placebo, and monitor vital status. Primary mortality outcomes are defined as all-cause mortality rate (deaths per 1000 person-years) after 2.5\u2009years from the first enrollment in 1) children 1\u201359\u2009months old comparing the azithromycin 1\u201359 and placebo arms, 2) children 1\u201311\u2009months old comparing the azithromycin 1\u201311 and placebo arm, and 3) children 12\u201359\u2009months in the azithromycin 1\u201311 and azithromycin 1\u201359 arms. In the Dosso region, 50 communities from each arm will be followed to monitor antimicrobial resistance. Primary resistance outcomes will be assessed after 2\u2009years of distributions and include 1) prevalence of genetic determinants of macrolide resistance in nasopharyngeal samples from children 1\u201359\u2009months old, and 2) load of genetic determinants of macrolide resistance in rectal samples from children 1\u201359\u2009months old.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>As high-mortality settings consider this intervention, the results of this trial will provide evidence to support programmatic and policy decision-making on age-based strategies for azithromycin distribution to promote child survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>This trial was registered on January 13, 2020 (clinicaltrials.gov:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04224987\">NCT04224987<\/jats:ext-link>).<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12889-021-10824-7","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T09:03:19Z","timestamp":1619686999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Age-based targeting of biannual azithromycin distribution for child survival in Niger: an adaptive cluster-randomized trial protocol (AVENIR)"],"prefix":"10.1186","volume":"21","author":[{"name":"the AVENIR Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran S.","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Arzika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdou","family":"Amza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramatou","family":"Maliki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sani","family":"Ousmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boubacar","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beido","family":"Nassirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alio Karamba","family":"Mankara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoul Naser","family":"Harouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Colby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Lebas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E.","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis C.","family":"Porco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin F.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Lietman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"issue":"10100","key":"10824_CR1","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0140-6736(17)31833-0","volume":"390","author":"GBD 2016 Child Mortality Collaborators","year":"2017","unstructured":"GBD 2016 Child Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1084\u2013150.","journal-title":"Lancet"},{"issue":"10108","key":"10824_CR2","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/S0140-6736(17)31758-0","volume":"390","author":"N Golding","year":"2017","unstructured":"Golding N, Burstein R, Longbottom J, Browne AJ, Fullman N, Osgood-Zimmerman A, et al. Mapping under-5 and neonatal mortality in Africa, 2000-15: a baseline analysis for the Sustainable Development Goals. Lancet. 2017;390(10108):2171\u201382.","journal-title":"Lancet."},{"key":"10824_CR3","volume-title":"The 2030 agenda for sustainable development","author":"United Nations Transforming our world","year":"2015","unstructured":"United Nations Transforming our world. The 2030 agenda for sustainable development. New York: United Nations; 2015."},{"issue":"4","key":"10824_CR4","doi-asserted-by":"publisher","first-page":"e0005402","DOI":"10.1371\/journal.pntd.0005402","volume":"11","author":"PM Emerson","year":"2017","unstructured":"Emerson PM, Hooper PJ, Sarah V. Progress and projections in the program to eliminate trachoma. PLoS Negl Trop Dis. 2017;11(4):e0005402.","journal-title":"PLoS Negl Trop Dis."},{"key":"10824_CR5","unstructured":"International Trachoma Initiative Zithromax Shipments: Cumulative Treatments Shipped 2020 [Available from: https:\/\/www.trachoma.org\/."},{"issue":"9","key":"10824_CR6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2009.1266","volume":"302","author":"TC Porco","year":"2009","unstructured":"Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA. 2009;302(9):962\u20138.","journal-title":"JAMA."},{"issue":"7","key":"10824_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/cid\/cir069","volume":"52","author":"JD Keenan","year":"2011","unstructured":"Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis. 2011;52(7):883\u20138.","journal-title":"Clin Infect Dis."},{"issue":"11","key":"10824_CR8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/INF.0000000000001992","volume":"37","author":"KS O'Brien","year":"2018","unstructured":"O'Brien KS, Cotter SY, Amza A, Kadri B, Nassirou B, Stoller NE, et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of the PRET cluster-randomized trial in Niger. Pediatr Infect Dis J. 2018;37(11):1082\u20136.","journal-title":"Pediatr Infect Dis J."},{"issue":"17","key":"10824_CR9","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1056\/NEJMoa1715474","volume":"378","author":"JD Keenan","year":"2018","unstructured":"Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, et al. Azithromycin to reduce childhood mortality in sub-Saharan Africa. N Engl J Med. 2018;378(17):1583\u201392.","journal-title":"N Engl J Med."},{"issue":"2","key":"10824_CR10","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.1016\/S2214-109X(19)30540-6","volume":"8","author":"JD Keenan","year":"2020","unstructured":"Keenan JD, Arzika AM, Maliki R, Elh Adamou S, Ibrahim F, Kiemago M, et al. Cause-specific mortality of children younger than 5 years in communities receiving biannual mass azithromycin treatment in Niger: verbal autopsy results from a cluster-randomised controlled trial. Lancet Glob Health. 2020;8(2):e288\u2013e95.","journal-title":"Lancet Glob Health."},{"issue":"23","key":"10824_CR11","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMc1901535","volume":"380","author":"T Doan","year":"2019","unstructured":"Doan T, Arzika AM, Hinterwirth A, Maliki R, Zhong L, Cummings S, et al. Macrolide resistance in MORDOR I - a cluster-randomized trial in Niger. N Engl J Med. 2019;380(23):2271\u20133.","journal-title":"N Engl J Med."},{"issue":"1","key":"10824_CR12","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S1473-3099(18)30444-4","volume":"19","author":"KS O'Brien","year":"2019","unstructured":"O'Brien KS, Emerson P, Hooper PJ, Reingold AL, Dennis EG, Keenan JD, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis. 2019;19(1):e14\u201325.","journal-title":"Lancet Infect Dis."},{"issue":"23","key":"10824_CR13","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1817213","volume":"380","author":"JD Keenan","year":"2019","unstructured":"Keenan JD, Arzika AM, Maliki R, Boubacar N, Elh Adamou S, Moussa Ali M, et al. Longer-term assessment of azithromycin for reducing childhood mortality in Africa. N Engl J Med. 2019;380(23):2207\u201314.","journal-title":"N Engl J Med."},{"key":"10824_CR14","volume-title":"WHO guideline on mass drug administration of azithromycin to children under five years of age to promote child survival","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. WHO guideline on mass drug administration of azithromycin to children under five years of age to promote child survival. Geneva: World Health Organization; 2020."},{"issue":"3","key":"10824_CR15","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.4269\/ajtmh.19-0328","volume":"103","author":"CE Oldenburg","year":"2020","unstructured":"Oldenburg CE, Arzika AM, Maliki R, Lin Y, O'Brien KS, Keenan JD, et al. Optimizing the number of child deaths averted with mass azithromycin distribution. Am J Trop Med Hyg. 2020;103(3):1308\u201310.","journal-title":"Am J Trop Med Hyg."},{"issue":"15","key":"10824_CR16","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJMp1806634","volume":"379","author":"M Chowkwanyun","year":"2018","unstructured":"Chowkwanyun M, Bayer R, Galea S. \u201cPrecision\u201d public health \u2014 between novelty and hype. N Engl J Med. 2018;379(15):1398\u2013400.","journal-title":"N Engl J Med."},{"issue":"1","key":"10824_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ije\/14.1.32","volume":"14","author":"G Rose","year":"1985","unstructured":"Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14(1):32\u20138.","journal-title":"Int J Epidemiol."},{"issue":"4","key":"10824_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/sim.4780030421","volume":"3","author":"S Yusuf","year":"1984","unstructured":"Yusuf S, Collins R, Peto R. Why do we need large, simple randomized trials? Stat Med. 1984;3(4):409\u201322.","journal-title":"Stat Med."},{"key":"10824_CR19","doi-asserted-by":"publisher","DOI":"10.1201\/9781584888178","volume-title":"Cluster Randomized Trials","author":"RJ Hayes","year":"2009","unstructured":"Hayes RJ, Moulton LH. Cluster Randomized Trials. Boca Raton: CRC\/Taylor and Francis; 2009."},{"issue":"10","key":"10824_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","volume":"18","author":"DC Angus","year":"2019","unstructured":"Angus DC, Alexander BM, Berry S, Buxton M, Lewis R, Paoloni M, et al. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov. 2019;18(10):797\u2013807.","journal-title":"Nat Rev Drug Discov."},{"issue":"3","key":"10824_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med."},{"issue":"7778","key":"10824_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41586-019-1545-0","volume":"574","author":"R Burstein","year":"2019","unstructured":"Burstein R, Henry NJ, Collison ML, Marczak LB, Sligar A, Watson S, et al. Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature. 2019;574(7778):353\u20138.","journal-title":"Nature."},{"issue":"4","key":"10824_CR23","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1167\/iovs.02-0234","volume":"44","author":"B Mu\u00f1oz","year":"2003","unstructured":"Mu\u00f1oz B, Solomon AW, Zingeser J, Barwick R, Burton M, Bailey R, et al. Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. Invest Ophthalmol Vis Sci. 2003;44(4):1464\u20139.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"2","key":"10824_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/pst.1845","volume":"17","author":"SS Villar","year":"2018","unstructured":"Villar SS, Bowden J, Wason J. Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends? Pharm Stat. 2018;17(2):182\u201397.","journal-title":"Pharm Stat."},{"issue":"22","key":"10824_CR25","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1056\/NEJMra1709701","volume":"378","author":"A Dmitrienko","year":"2018","unstructured":"Dmitrienko A, D'Agostino RB Sr. Multiplicity considerations in clinical trials. N Engl J Med. 2018;378(22):2115\u201322.","journal-title":"N Engl J Med."},{"issue":"6","key":"10824_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10654-011-9554-9","volume":"26","author":"MJ Knol","year":"2011","unstructured":"Knol MJ, VanderWeele TJ, Groenwold RH, Klungel OH, Rovers MM, Grobbee DE. Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol. 2011;26(6):433\u20138.","journal-title":"Eur J Epidemiol."},{"key":"10824_CR27","first-page":"33","volume":"3","author":"TJ VanderWeele","year":"2014","unstructured":"VanderWeele TJ, Knol MJ. A tutorial on interaction. Epidemiol Methods. 2014;3:33\u201372.","journal-title":"Epidemiol Methods."},{"key":"10824_CR28","volume-title":"Resampling-based multiple testing: examples and methods for P-value adjustment","author":"PH Westfall","year":"1993","unstructured":"Westfall PH, Young SS. Resampling-based multiple testing: examples and methods for P-value adjustment. New York: Wiley; 1993."},{"issue":"1","key":"10824_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02595811","volume":"12","author":"Y Ge","year":"2003","unstructured":"Ge Y, Dudoit S, Speed TP. Resampling-based multiple testing for microarray data analysis. Test. 2003;12(1):1\u201377.","journal-title":"Test."},{"key":"10824_CR30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol. 1995;57:289\u2013300.","journal-title":"J R Stat Soc B Methodol."},{"issue":"7","key":"10824_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.spl.2010.12.018","volume":"81","author":"R Simon","year":"2011","unstructured":"Simon R, Simon NR. Using randomization tests to preserve type I error with response-adaptive and covariate-adaptive randomization. Stat Probab Lett. 2011;81(7):767\u201372.","journal-title":"Stat Probab Lett."},{"issue":"526","key":"10824_CR32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1259\/0007-1285-44-526-793","volume":"44","author":"JL Haybittle","year":"1971","unstructured":"Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol. 1971;44(526):793\u20137.","journal-title":"Br J Radiol."},{"issue":"1","key":"10824_CR33","doi-asserted-by":"publisher","first-page":"010305","DOI":"10.7189\/jogh.09.010305","volume":"9","author":"CC Tam","year":"2019","unstructured":"Tam CC, Offeddu V, Lim JM, Voo TC. One drug to treat them all: ethical implications of the MORDOR trial of mass antibiotic administration to reduce child mortality. J Glob Health. 2019;9(1):010305.","journal-title":"J Glob Health."},{"issue":"3","key":"10824_CR34","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.4269\/ajtmh.18-1004","volume":"103","author":"AP Oron","year":"2019","unstructured":"Oron AP, Burstein R, Mercer LD, Arzika AM, Kalua K, Mrango Z, et al. Effect modification by baseline mortality in the MORDOR azithromycin trial. Am J Trop Med Hyg. 2019;103(3):1295\u2013300.","journal-title":"Am J Trop Med Hyg."},{"issue":"23","key":"10824_CR35","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa1811400","volume":"380","author":"D Chandramohan","year":"2019","unstructured":"Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, et al. Effect of adding azithromycin to seasonal malaria chemoprevention. N Engl J Med. 2019;380(23):2197\u2013206.","journal-title":"N Engl J Med."},{"issue":"3","key":"10824_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1542\/peds.2014-2026","volume":"135","author":"MD Eberly","year":"2015","unstructured":"Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in early infancy and pyloric stenosis. Pediatrics. 2015;135(3):483\u20138.","journal-title":"Pediatrics."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-10824-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-021-10824-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-10824-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T20:07:38Z","timestamp":1724962058000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-021-10824-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10824"],"URL":"https:\/\/doi.org\/10.1186\/s12889-021-10824-7","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"4 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of California San Francisco Institutional Review Board has given ethical approval for the trial and will review the trial annually (19\u201328287). The Comit\u00e9 National \u00c9thique pour la Recherche en Sant\u00e9 in Niger granted ethical approval before study activities began (DELIBERATION No. 041\/2020\/CNERS).Verbal consent will be obtained from the head of household for participation in the census and from guardians for treatment administration. For children aged 30 to 42\u2009days old, written consent will be obtained via caregiver thumbprint, as requested by the UCSF IRB given the possible risk of infantile hypertrophic pyloric stenosis with macrolides in this age group []. Verbal consent will be obtained from regional, district and community leaders before recruiting any participants into the study. For specimen collections, additional written informed consent will be obtained from participants and\/or caregivers before data collection. There is no financial cost to the participant and there is no reimbursement for overall participation in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"822"}}